25 results on '"Voto, L."'
Search Results
2. Effects of butyrate against pediatric obesity: the Bapo randomized-controlled trial
- Author
-
Coppola S., Nocerino R., Paparo L., Voto L., Bedogni G., De Filippis F., Ercolini D., Berni Cannai R., Coppola, S., Nocerino, R., Paparo, L., Voto, L., Bedogni, G., De Filippis, F., Ercolini, D., and Berni Cannai, R.
- Published
- 2022
3. The gut microbiome-derived metabolite butyrate is able to exert a protective action against the deleterious effects of ultra-processed foods in facilitating food allergy
- Author
-
Paparo L., Bruno C., Punzo E., Voto L., Coppola S., De Giovanni di Santa Severina A. F., Luzzetti A., D'Ausilio D., Lettieri M., Carucci L., Berni Canani R, Paparo, L., Bruno, C., Punzo, E., Voto, L., Coppola, S., De Giovanni di Santa Severina, A. F., Luzzetti, A., D'Ausilio, D., Lettieri, M., Carucci, L., and Berni Canani, R
- Published
- 2022
4. The evaluation of tolerance rate and the immune tolerance acquisition in children with cow's milk allergy switching from amino acid-based formula to extensively hydrolyzed casein formula: the SDACMA project
- Author
-
Nocerino R., Cosenza L., Lettieri M., Carucci L., Coppola S., Voto L., Paparo L., Berni Canani R, Nocerino, R., Cosenza, L., Lettieri, M., Carucci, L., Coppola, S., Voto, L., Paparo, L., and Berni Canani, R
- Published
- 2022
5. Exposure to dietary advanced glycation end-products facilitated allergic response in peripheral blood mononuclear cells from children at risk for atopy
- Author
-
Paparo L., Bruno C., Punzo E., Voto L., Coppola S., De Giovanni di Santa Severina A. F., Lettieri M., Crucci L., Berni Canani R, Paparo, L., Bruno, C., Punzo, E., Voto, L., Coppola, S., De Giovanni di Santa Severina, A. F., Lettieri, M., Crucci, L., and Berni Canani, R
- Published
- 2022
6. EE339 Economic Impact Analysis of the Incorporation of the Elecsys sFlt-1/PIGF Ratio for the Diagnosis and Follow-up of Pregnant Women with Suspected Preeclampsia in Argentina
- Author
-
Garay, OU, primary, Guinazu, G, additional, Basualdo, N, additional, D.I., Marco I, additional, Zilberman, J, additional, and Voto, L, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Butyrate against paediatric obesity: results of the BAPO trial
- Author
-
161. Coppola S., Nocerino R., Paparo L., Di Scala C., Voto L., Luzzetti A., Berni Canani R, XLI Congresso Nazionale SINU, 16, 1. Coppola S., Nocerino, R., Paparo, L., Di Scala, C., Voto, L., Luzzetti, A., and Berni Canani, R
- Published
- 2021
8. Obstetric patients in the intensive care unit (ICU): hematologic aspects: WH07
- Author
-
Grand, B, Alcantara, M G, Orti, J, Lapidus, A, and Voto, L S
- Published
- 2014
9. Equity in coronavirus disease 2019 vaccine development and deployment
- Author
-
Modi N, Ayres-de-Campos D, Bancalari E, Benders M, Briana D, Di Renzo GC, Fonseca EB, Hod M, Poon L, Cortes MS, Simeoni U, Tscherning C, Vento M, Visser GHA, and Voto L
- Subjects
Task Force on Research Specific to Pregnant Women and Lactating Women, World Health Organization, antibody-dependent enhancement, clinical trials, coronavirus disease 2019, gender-equity, lactation, neonatal immunity, pregnancy, randomized trials, research-equity, safety and efficacy, severe acute respiratory syndrome coronavirus 2, vaccine development, women - Abstract
The coronavirus disease 2019 pandemic exposed weaknesses in multiple domains and widened gender-based inequalities across the world. It also stimulated extraordinary scientific achievement by bringing vaccines to the public in less than a year. In this article, we discuss the implications of current vaccination guidance for pregnant and lactating women, if their exclusion from the first wave of vaccine trials was justified, and if a change in the current vaccine development pathway is necessary. Pregnant and lactating women were not included in the initial severe acute respiratory syndrome coronavirus 2 vaccine trials. Therefore, perhaps unsurprisingly, the first vaccine regulatory approvals have been accompanied by inconsistent advice from public health, governmental, and professional authorities around the world. Denying vaccination to women who, although pregnant or breastfeeding, are fully capable of autonomous decision making is a throwback to a paternalistic era. Conversely, lack of evidence generated in a timely manner, upon which to make an informed decision, shifts responsibility from research sponsors and regulators and places the burden of decision making upon the woman and her healthcare advisor. The World Health Organization, the Task Force on Research Specific to Pregnant Women and Lactating Women, and others have highlighted the long-standing disadvantage experienced by women in relation to the development of vaccines and medicines. It is uncertain whether there was sufficient justification for excluding pregnant and lactating women from the initial severe acute respiratory syndrome coronavirus 2 vaccine trials. In future, we recommend that regulators mandate plans that describe the development pathway for new vaccines and medicines that address the needs of women who are pregnant or lactating. These should incorporate, at the outset, a careful consideration of the balance of the risks of exclusion from or inclusion in initial studies, patient and public perspectives, details of "developmental and reproductive toxicity" studies, and approaches to collect data systematically from participants who are unknowingly pregnant at the time of exposure. This requires careful consideration of any previous knowledge about the mode of action of the vaccine and the likelihood of toxicity or teratogenicity. We also support the view that the default position should be a "presumption of inclusion," with exclusion of women who are pregnant or lactating only if justified on specific, not generic, grounds. Finally, we recommend closer coordination across countries with the aim of issuing consistent public health advice.
- Published
- 2021
10. Profilaxis del tromboembolismo venoso en embarazo y puerperio: actualización en tiempos de infección por COVID-19
- Author
-
Grand, Beatriz, González Alcántara, M M, Damico, V, Ilzarbe, A B, Orti, J, Voto, L S, Grand, Beatriz, González Alcántara, M M, Damico, V, Ilzarbe, A B, Orti, J, and Voto, L S
- Abstract
Coronavirus (COVID-19) disease is a highly contagious pandemic disease caused by a novel coronavirus (SARS-CoV-2). It appeared in Wuhan, Hubei, province of China, in November 2019. It may predispose patients to thrombotic disease due to excessive inflammation (cytokine storm), platelet activation, endothelial dysfunction, and stasis. Increased odds of in hospital deaths were associated with remarkably high D-dimer values. Actually, called COVID-19 associated coagulopathy, in particular in pregnancy it is an exceptional challenge for the health systems.There are limited case series reporting the impact on women affected by COVID-19. The first case in our country appeared in March 2020. Pregnancy fulfils the three criteria of Virchow’s triad. The optimalthromboprophylaxis in COVID-19 pregnant women is not known. We work with the combination of the available information at time of this publication, together with our experience and adapted to our hospital requirements. Low molecular weight heparin (LMWH) enoxaparin 40 mg/d was prescribed to pregnant women COVID-19. Outpatient prolongation of thromboprophylaxis depends on risk stratification. In this article we review the information from other countries, and we describe our venous thromboprophylaxis recommendations., La enfermedad por coronavirus 2019 (COVID-19), considerada desde marzo por la OMS una pandemia, es una infección altamente contagiosa causada por un nuevo coronavirus responsable del síndrome respiratorio agudo relacionado al coronavirus 2 (SARS-CoV-2). Apareció en Wuhan, Hubei, provincia de China, en noviembre de 2019. Puede predisponer a los pacientes a enfermedad trombótica debido a la excesiva inflamación (tormenta de citoquinas), activación plaquetaria, disfunción endotelial y estasis. El incremento del riesgo de muerte se asocia con un marcado incremento de los valores de dímero-D.Actualmente es considerada como una coagulopatía asociada a COVID-19 (CAC). En particular, en embarazo, la infección por COVID-19 es un desafío excepcional para el sistema de salud. El primer caso en Argentina apareció en marzo 2020. En el embarazo se presentan los tres elementos de la clásica tríada de Virchow. El régimen óptimo de tromboprofilaxis en embarazadas con COVID-19 no está establecido. Nosotros trabajamos en base a lo reportado en publicaciones, en conjunto con nuestra experiencia y adaptado a los requerimientos hospitalarios. En embarazadas COVID-19 positivas que se hospitalizan se recomienda la administración de heparina de bajo peso molecular 40 mg/día enoxaparina o heparina no fraccionada en caso de cercanía de parto.La prolongación de la tromboprofilaxis en pacientes externados, ya sea que continúen su embarazo o luego del parto, requiere de una estratificación en base a sus factores de riesgo y evolución del cuadroinfeccioso. En este trabajo revisamos la experiencia de otros países y describimos nuestras recomendaciones.
- Published
- 2020
11. CLASP - A RANDOMIZED TRIAL OF LOW-DOSE ASPIRIN FOR THE PREVENTION AND TREATMENT OF PREECLAMPSIA AMONG 9364 PREGNANT-WOMEN
- Author
-
BEROYZ, G, CASALE, R, FARREIROS, A, PALERMO, M, MARGULIES, M, VOTO, L, FABREGUES, G, RAMALINGAM, R, DAVIES, T, BRYCE, R, BOYD, W, CARMODY, F, KING, J, VACCA, A, FAY, R, WALTERS, W, ANTONAS, B, BENNETT, P, BROOM, T, CROWTHER, C, DERHAM, R, GEORGE, K, HAGUE, W, HASENHOHR, G, HEYSEN, D, KORNMAN, L, OLOUGHLIN, S, MORRIS, D, PRIDMORE, B, ROBINSON, J, SVIGOS, D, SWEET, R, BEALE, M, BENNETT, M, BOSCH, E, FISHER, C, HORRAUTZ, S, SYMINGTON, I, SZIRT, A, FORBES, K, FREEMAN, A, POPPER, E, WILSON, J, PERMEZEL, M, BOWDITCH, J, REYNOLDS, G, MOULINASSE, R, BIETLOT, Y, KIRKPATRICK, C, COULON, R, DELVOYE, P, DEMATOS, C, SIMONINI, S, LEJEUNE, B, NEERDAELS, C, ALEXANDER, S, GOESSENS, L, HANSSENS, M, SPITZ, B, VANASSCHE, A, WECKHUYSEN, R, PARBOOSINGH, J, HARMAN, C, REY, E, BURROWS, R, BELCHER, J, GARNER, P, SYLVAIN, J, NIMROD, C, THOMAS, B, DEININGER, F, LAO, T, LI, C, FRIEDMAN, S, BORNSTEIN, J, SHALIT, A, MATZKEL, A, POMERANZ, M, GELSNER, M, MANKUTA, D, WIZNITZER, A, LEVINE, S, ADEEB, N, CHANDRAN, R, NASRI, N, SHARIFF, J, ANSELL, D, LAKE, Y, GOROCHOVA, L, MERIAKRI, V, ROMANUGA, N, DOTZ, I, SHEUV, B, VIKHLYAEVA, E, ANDREEV, K, GOLUBEVA, L, GORODCOV, V, ADELANTADO, J, SANTONJA, J, HOLMBERG, H, BUCHHAVE, P, LEANDERSSON, U, LILJESTRAND, J, RYDHSTROEM, H, SWEDIN, G, BJORKLUND, A, GENNSER, G, SANDEN, M, DAHLGREN, S, HAMMARBACK, S, SMEDS, A, SIDENVALL, M, ENEROTH, E, SZABOLCS, A, DANIELSSON, I, LINDQVIST, P, HOGSTEDT, S, WALLENBURG, H, BREMER, H, BRIET, J, DEBIEMEYERINK, A, DONKERS, B, LAMPING, P, SCHIERBEEK, J, VANDERLEEUWHARMSEN, L, THE, H, VANBODEGOM, F, VANEGMONDLINDEN, A, FLU, P, KUIJKEN, J, MORREL, B, STRAUB, M, VIERHOUT, M, KEIRSE, M, VANROOSMALEN, J, HOHNER, C, HUTTEN, J, BENNEN, J, ROEX, A, WIJFFELS, T, OOSTERHOFF, H, OTTEN, J, VANDERKLEI, T, RAMONDT, J, VANDERMOER, P, DEGRAAFF, J, SIJSMA, E, DEGREVE, O, SMIT, D, SMULDERS, P, NIJHUIS, J, ZONDERVAN, H, LIND, J, SCHOOT, B, MONKHORST, M, STUT, J, VANDAM, L, VANOTTERLO, L, VLAANDEREN, W, EGGENS, J, SANTEMA, J, VERHOEFF, A, HAMID, S, JOHN, I, KHAN, G, SHAH, S, SHEIKH, E, SINHA, C, ABRAMOVICH, D, CAMPBELL, D, FISHER, P, GALL, S, HALL, M, JANDIAL, V, PARKIN, D, SMITH, N, SUTHERLAND, H, SWAPP, G, TEMPLETON, A, TERRY, P, KALAM, A, MAGEE, S, MARTIN, D, SPEARING, G, ALDERMAN, B, MURRAY, A, SUTHERST, J, HYATT, D, SAUNDERS, P, BURGESS, S, COCHRANE, G, WHITE, A, ARMSTRONG, M, MCNICHOL, E, OSBOURNE, G, PRICE, J, CRICHTON, J, EVANS, D, ANDERSON, R, HULL, M, JAMES, D, NIVEN, P, STIRRAT, G, WARDLE, P, GARDNER, P, PADGETT, L, ALAILY, A, NASH, G, GINZ, B, SMITH, M, RICHARDS, C, ARMAR, A, ARMSTRONG, N, MANNING, E, PERSAD, K, COLLINGWOOD, M, COLLINS, R, CROWTHER, J, FARRELL, B, HAFNER, B, HANDOLL, H, HEINEMAN, J, KNIGHT, S, MEAD, G, RADLEY, A, SPENCE, S, REID, W, TREHARNE, I, HEASLEY, R, LOWRY, D, MYLES, T, WALLACE, R, GEALS, M, GORDON, G, TRAIN, T, HUTCHON, D, MACDONALD, J, STOREY, R, ANDERSON, G, WORTH, R, ERIAN, J, MCQUEEN, J, TATFORD, E, TERRY, M, NEALE, R, HOWAT, R, KENNEDY, J, MACNAUGHTON, M, MCEWAN, H, WALKER, J, HUTCHESON, R, KEMP, V, READ, M, SIMMS, M, SWINGLER, G, HUSEMEYER, R, CHAPMAN, M, MAXWELL, D, ELDER, M, FUSI, L, HAWKINS, D, NICOLINI, U, WINSTON, R, BURTON, E, FAIRBANK, J, SIMMONS, S, SPING, J, TRICKEY, N, GILLARD, M, HUDSON, C, SETCHELL, M, WATHEN, N, CANTY, S, WHITELEY, P, CAMPBELL, J, FEENEY, J, HAY, D, IMRIE, A, PALMER, A, PURDIE, D, SPECK, E, TYRRELL, S, MCLEAN, J, BROWN, V, DUNCAN, S, JOHNSON, D, MILLAR, D, BUCKLEY, D, CHARNOCK, M, DOVE, P, ELLIS, J, GILLMER, M, MCVITTIE, J, MANNION, V, REDMAN, C, SELLERS, S, TURNBULL, A, NEWMAN, M, CAMPBELL, S, CARDOSO, L, GIBB, D, HARRINGTON, K, PARSONS, J, NICOLAIDES, K, STUDD, J, DIXON, R, GIE, C, PICKLES, C, SEAR, R, GRAHAM, R, KIRWAN, P, SMITH, G, ANWAR, M, ALAZZAWI, F, DAVIDSON, A, DECHAZEL, R, DRIFE, J, GILL, F, LANG, G, MACAFEE, J, MACVICAR, J, NAFTALIN, N, NEUBERG, R, TAYLOR, D, LEAVER, E, TIMOTHY, I, BREESON, A, LAMB, M, VELACOTT, I, VERNER, V, HORWELL, D, LOBB, M, SELIGMAN, S, SCOTT, A, HALL, S, MACKENZIE, W, SMITH, E, VETHANAVAGAN, S, VERZIN, J, WEIR, P, WHITE, R, CLARK, H, FAWDRY, R, LYNCH, C, MCCUNE, G, BOWENSIMPKINS, P, CALVERT, J, EMERY, S, JACKSON, W, STOKES, I, WARD, A, BROWNING, A, COX, C, LITTLE, D, STIBBE, H, MCINTOSH, A, SNODGRASS, C, WAGSTAFF, T, HOWIE, P, BIBBY, J, DAVIES, W, ELLIOTT, B, SHAXTED, E, MCGARRY, J, DAW, E, BAKER, K, CLUBB, A, GOUGH, J, GRANT, M, MENON, V, OBHARI, M, OBRIEN, P, BROWN, R, RYALL, A, WALTON, S, BAKER, J, BRUCE, J, LIU, D, JOHNSON, I, TYACK, A, COWIE, D, NYSENBAUM, A, BAMFORD, P, GARRIOCH, D, HILL, J, GRANT, A, FELTON, D, HACKMAN, B, FALCONER, A, FREEMAN, F, GREENE, K, JACKSON, J, HUNTER, G, GRATTON, D, MAULIK, T, YOUSSEF, H, BANWELL, G, HARTWELL, R, WILSON, P, BOND, A, FORBESSMITH, P, BARRON, L, DAVISON, J, DUNLOP, W, LIND, T, TACCHI, D, BALFOUR, R, MUTCH, L, COLTART, T, DESWIET, M, EDMONDS, D, LOEFFLER, F, MALVERN, J, OSBOURNE, J, RODECK, C, SIMS, C, SPENCER, J, BONE, C, MACDONALD, A, DREW, N, BALLARD, R, THONET, R, HANNA, L, MORCOS, S, HOLT, E, COOPER, J, CALLEN, P, FOZZARD, C, GRUNDY, M, STANLEY, S, DANIEL, D, GOLDING, R, WIENER, J, BUCKINGHAM, M, HEARD, M, LETCHWORTH, A, BOOMLA, K, CLARK, A, GRUDZINSKAS, J, HARTGILL, J, ORAM, D, ROBSON, J, SAVAGE, W, BLUNT, V, LANE, J, OWEN, A, REDFORD, D, BEARD, R, BOSTOCK, J, MEASDAY, B, MELVILLE, H, DORNAN, J, TRAUB, A, UTIDJIAN, M, AULD, A, KRASZEWSKI, A, MACK, D, MCDOUGALL, N, MOWAT, J, DOCHERTY, P, MCKENNA, D, SMEDLEY, G, WILDE, J, SMITH, R, WATNEY, P, MCDONNELL, J, TROMAMS, P, CALDER, A, GLASIER, A, GREER, I, JOHNSTONE, F, LISTON, W, LIVINGSTONE, J, NEILSON, J, SMITH, S, WEST, C, BULLOUGH, C, JONES, A, MACKAY, G, COOPER, K, RUOSS, C, JOYCE, D, MCCOY, D, MCLEOD, F, SAVAGE, P, SMITH, P, TURNER, G, KANE, L, ROSENBERG, D, SHANNON, R, BROMHAM, D, BUCHAN, P, CROMPTON, A, JARVIS, G, LILFORD, R, MACDONALD, H, THORNTON, J, PINKER, G, BEVAN, J, FRANCIS, J, KETTLE, M, HOLMES, H, KERRWILSON, R, SUTTON, M, BEYNON, J, HOOKER, J, FERGUSSON, I, MORTON, K, TAYLOR, R, DAVIS, J, LOW, R, STEWART, J, ASHWORTH, F, SOONAWALLA, K, TEBBUTT, I, USHERWOOD, M, VOIGT, J, COHEN, S, GODFREY, K, MCNAB, G, MURRAY, B, GUDGEON, D, FOULKES, J, STANNARD, P, JAMSHIDI, R, MULHOLLAND, J, BOND, E, DUNLOP, J, FOGARTY, P, BRANT, H, LACHELIN, L, LLOYDJONES, R, SIDDLE, N, SILVERSTONE, A, STEELE, S, WARD, R, EDDIE, D, VERNONPARRY, J, CIETAK, K, KENNEDY, C, REED, M, SANTCASSIA, L, BEGG, H, FRAMPTON, J, GRIFFIN, D, LEWIS, B, NESTROP, A, SHERIDAN, R, TIPTON, R, BOBER, S, BROUGH, F, STAFFORD, J, HOUSE, M, PAWSON, M, REES, D, VENN, R, ANDERSON, T, HUGHES, J, REGINALD, P, HENSON, G, MORGAN, H, ALLEN, I, HANNAY, W, LENNOX, C, CALLENDER, R, MCLEAN, R, GOLDKRAND, J, and FIDALGO, C
- Subjects
medicine.medical_specialty ,Randomized controlled trial ,law ,business.industry ,Internal medicine ,medicine ,General Medicine ,medicine.disease ,business ,law.invention ,Preeclampsia ,Low dose aspirin - Published
- 2016
- Full Text
- View/download PDF
12. WS15‐07Assessment of a formula using Doppler velocimetry to calculate fetal hemoglobin (Hb)
- Author
-
Voto, L. S., primary, Mulki, O. B., additional, Zapaterio, J. L., additional, Falco, A., additional, Mathet, E. R., additional, Lede, R. L., additional, and Margulies, M., additional
- Published
- 2000
- Full Text
- View/download PDF
13. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study.
- Author
-
Voto, L S, primary, Lapidus, A M, additional, Catuzzi, P, additional, Uranga Imaz, F, additional, Zin, C, additional, and Margulies, M, additional
- Published
- 1992
- Full Text
- View/download PDF
14. Butyrate as a bioactive human milk protective component against food allergy
- Author
-
Lorella Paparo, F. Messina, Annalisa Agangi, Francesco Montella, Cristina Bruno, Marcello Napolitano, Annibale Puca, Antonio Amoroso, Giusy Della Gatta, Rita Nocerino, Giovanna Trinchese, Laura Pisapia, Annalisa Passariello, Roberto Berni Canani, Maria Pina Mollica, Elena Ciaglia, Carmen Di Scala, Carmen De Caro, Roberto Russo, Luana Voto, Antonio Calignano, Margherita Di Costanzo, Rosita Aitoro, Paparo, L., Nocerino, R., Ciaglia, E., Di Scala, C., De Caro, C., Russo, R., Trinchese, G., Aitoro, R., Amoroso, A., Bruno, C., Di Costanzo, M., Passariello, A., Messina, F., Agangi, A., Napolitano, M., Voto, L., Gatta, G. D., Pisapia, L., Montella, F., Mollica, M. P., Calignano, A., Puca, A., and Berni Canani, R.
- Subjects
immune tolerance ,short‐chain fatty acids ,short-chain fatty acids ,Immunology ,Stimulation ,Butyrate ,Pharmacology ,medicine.disease_cause ,Peripheral blood mononuclear cell ,Immune tolerance ,In vivo ,medicine ,Animals ,Immunology and Allergy ,tolerogenic mechanism ,Milk, Human ,Chemistry ,breast milk ,In vitro ,Gastrointestinal Microbiome ,Butyrates ,Allergic response ,Original Article ,Basic and Translational Allergy Immunology ,ORIGINAL ARTICLES ,short-chain fatty acid ,Food Hypersensitivity ,Oxidative stress - Abstract
Background Food allergy (FA) is a growing health problem worldwide. Effective strategies are advocated to limit the disease burden. Human milk (HM) could be considered as a protective factor against FA, but its mechanisms remain unclear. Butyrate is a gut microbiota‐derived metabolite able to exert several immunomodulatory functions. We aimed to define the butyrate concentration in HM, and to see whether the butyrate concentration detected in HM is able to modulate the mechanisms of immune tolerance. Methods HM butyrate concentration from 109 healthy women was assessed by GS‐MS. The effect of HM butyrate on tolerogenic mechanisms was assessed in in vivo and in vitro models. Results The median butyrate concentration in mature HM was 0.75 mM. This butyrate concentration was responsible for the maximum modulatory effects observed in all experimental models evaluated in this study. Data from mouse model show that in basal condition, butyrate up‐regulated the expression of several biomarkers of gut barrier integrity, and of tolerogenic cytokines. Pretreatment with butyrate significantly reduced allergic response in three animal models of FA, with a stimulation of tolerogenic cytokines, inhibition of Th2 cytokines production and a modulation of oxidative stress. Data from human cell models show that butyrate stimulated human beta defensin‐3, mucus components and tight junctions expression in human enterocytes, and IL‐10, IFN‐γ and FoxP3 expression through epigenetic mechanisms in PBMCs from FA children. Furthermore, it promoted the precursors of M2 macrophages, DCs and regulatory T cells. Conclusion The study's findings suggest the importance of butyrate as a pivotal HM compound able to protect against FA., Human milk contains a significant level of the short‐chain fatty acid butyrate. At concentration detectable in human milk, butyrate effectively modulates several tolerogenic mechanisms involved in the protection against food allergy. The protective role of human milk against food allergy could be related, at least in part, to the presence of an effective concentration of butyrate
- Published
- 2020
- Full Text
- View/download PDF
15. Gut Microbiome as Target for Innovative Strategies Against Food Allergy
- Author
-
Roberto Berni Canani, Lorella Paparo, Rita Nocerino, Carmen Di Scala, Giusy Della Gatta, Ylenia Maddalena, Aniello Buono, Cristina Bruno, Luana Voto, Danilo Ercolini, Berni Canani, R, Paparo, L, Nocerino, R, Di Scala, C, Della Gatta, G, Maddalena, Y, Buono, A, Bruno, C, Voto, L, and Ercolini, D.
- Subjects
0301 basic medicine ,lcsh:Immunologic diseases. Allergy ,immune tolerance ,Immunology ,short chain fatty acids ,Review ,Biology ,Gut flora ,Immune tolerance ,law.invention ,03 medical and health sciences ,Probiotic ,0302 clinical medicine ,Food allergy ,law ,medicine ,Animals ,Humans ,Immunology and Allergy ,Dietary nutrients ,Microbiome ,gut microbiota metabolites ,gut microbiota ,dysbiosi ,Fatty Acids ,digestive, oral, and skin physiology ,Age Factors ,Disease Management ,mediterranean diet ,dysbiosis ,butyrate ,medicine.disease ,biology.organism_classification ,Gut microbiome ,Diet ,Gastrointestinal Microbiome ,030104 developmental biology ,probiotics ,Disease Susceptibility ,lcsh:RC581-607 ,Dysbiosis ,Food Hypersensitivity ,probiotic ,gut microbiota metabolite ,030215 immunology - Abstract
The dramatic increase in food allergy prevalence and severity globally requires effective strategies. Food allergy derives from a defect in immune tolerance mechanisms. Immune tolerance is modulated by gut microbiota function and structure, and microbiome alterations (dysbiosis) have a pivotal role in the development of food allergy. Environmental factors, including a low-fiber/high-fat diet, cesarean delivery, antiseptic agents, lack of breastfeeding, and drugs can induce gut microbiome dysbiosis, and have been associated with food allergy. New experimental tools and technologies have provided information regarding the role of metabolites generated from dietary nutrients and selected probiotic strains that could act on immune tolerance mechanisms. The mechanisms are multiple and still not completely defined. Increasing evidence has provided useful information on optimal bacterial species/strains, dosage, and timing for intervention. The increased knowledge of the crucial role played by nutrients and gut microbiota-derived metabolites is opening the way to a post-biotic approach in the stimulation of immune tolerance through epigenetic regulation. This review focused on the potential role of gut microbiome as the target for innovative strategies against food allergy.
- Published
- 2019
- Full Text
- View/download PDF
16. Dietary Treatment with Extensively Hydrolyzed Casein Formula Containing the Probiotic Lactobacillus rhamnosus GG Prevents the Occurrence of Functional Gastrointestinal Disorders in Children with Cow's Milk Allergy
- Author
-
Rita Nocerino, Laura Carucci, Roberto Berni Canani, Anna Maria Iannicelli, Luana Voto, Ylenia Maddalena, Linda Cosenza, Giorgio Bedogni, Carmen Di Scala, Margherita Di Costanzo, Giusy Della Gatta, Serena Coppola, Nocerino, R., Di Costanzo, M., Bedogni, G., Cosenza, L., Maddalena, Y., Di Scala, C., Della Gatta, G., Carucci, L., Voto, L., Coppola, S., Iannicelli, A. M., and Berni Canani, R.
- Subjects
Male ,Risk ,medicine.medical_specialty ,Gastrointestinal Diseases ,Milk allergy ,Gastroenterology ,law.invention ,Probiotic ,Lactobacillus rhamnosus ,Food allergy ,law ,Internal medicine ,Casein ,Immune Tolerance ,Prevalence ,Animals ,Humans ,Medicine ,Prospective Studies ,Child ,irritable bowel syndrome ,Food, Formulated ,food allergy ,gut microbiota ,biology ,Lacticaseibacillus rhamnosus ,business.industry ,Hydrolysis ,Probiotics ,Caseins ,functional constipation ,functional dyspepsia ,medicine.disease ,biology.organism_classification ,Diet ,functional abdominal pain ,Milk ,Treatment Outcome ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Cohort ,Functional constipation ,Cattle ,Female ,Milk Hypersensitivity ,business ,Cohort study - Abstract
To investigate whether the addition of the probiotic Lactobacillus rhamnosus GG (LGG) to the extensively hydrolyzed casein formula (EHCF) for cow's milk allergy (CMA) treatment could reduce the occurrence of functional gastrointestinal disorders (FGIDs).This cohort study included children with a positive history for CMA in the first year of life who were treated with EHCF alone or in combination with LGG and had evidence of immune tolerance acquisition to cow's milk for at least 12 months. FGID was diagnosed according to the Rome III diagnostic criteria by investigators unaware of previous treatment. A cohort of consecutive healthy children was also evaluated as a control population.A total of 330 subjects were included, 110 per cohort (EHCF, EHCF+LGG, and healthy controls). The rate of subjects with ≥1 FGID was significantly lower in the EHCF+LGG cohort compared with the EHCF cohort (40% vs 16.4%; P .05). In the EHCF+LGG cohort, a lower incidence was observed for all components of the main study outcome. The prevalence of FGIDs in the healthy cohort was lower than that in the EHCF cohort and similar to that in the EHCF+LGG cohort. The incidence rate ratio of FGIDs for the EHCF+LGG cohort vs the EHCF cohort (0.40; 95% CI, 0.25-0.65; P .001) was unmodified after correction for age at CMA diagnosis, breastfeeding, weaning time, and presence of a first-degree relative with an FGID.These results confirm the increased risk for developing FGIDs in children with CMA and suggest that EHCF+LGG could reduce this risk.
- Published
- 2019
- Full Text
- View/download PDF
17. Maternal Exposure to Endocrine-Disrupting Chemicals: Analysis of Their Impact on Infant Gut Microbiota Composition.
- Author
-
Vacca M, Calabrese FM, Loperfido F, Maccarini B, Cerbo RM, Sommella E, Salviati E, Voto L, De Angelis M, Ceccarelli G, Di Napoli I, Raspini B, Porri D, Civardi E, Garofoli F, Campiglia P, Cena H, and De Giuseppe R
- Abstract
Endocrine disruptors (EDCs) are chemicals that interfere with the endocrine system. EDC exposure may contribute to the development of obesity, type 2 diabetes, and cardiovascular diseases by impacting the composition of an infant's gut microbiota during the first 1000 days of life. To explore the relationship between maternal urinary levels of Bisphenol-A and phthalates (UHPLC-MS/MS), and the composition of the infant gut microbiota (16S rDNA) at age 12 months (T
3 ) and, retrospectively, at birth (T0 ), 1 month (T1 ), and 6 months (T2 ), stool samples from 20 infants breastfed at least once a day were analyzed. Metataxonomic bacteria relative abundances were correlated with EDC values. Based on median Bisphenol-A levels, infants were assigned to the over-exposed group (O, n = 8) and the low-exposed group (B, n = 12). The B-group exhibited higher gut colonization of the Ruminococcus torques group genus and the O-group showed higher abundances of Erysipelatoclostridium and Bifidobacterium breve . Additionally, infants were stratified as high-risk (HR, n = 12) or low-risk (LR, n = 8) exposure to phthalates, based on the presence of at least three phthalates with concentrations exceeding the cohort median values; no differences were observed in gut microbiota composition. A retrospective analysis of gut microbiota (T0 -T2 ) revealed a disparity in β-diversity between the O-group and the B-group. Considering T0 -T3 , the Linear Discriminant Effect Size indicated differences in certain microbes between the O-group vs. the B-group and the HR-group vs. the LR-group. Our findings support the potential role of microbial communities as biomarkers for high EDC exposure levels. Nevertheless, further investigations are required to deeply investigate this issue.- Published
- 2024
- Full Text
- View/download PDF
18. Autism Spectrum Disorder and collective catering service: results of the pilot study FOOD-AUT.
- Author
-
Conti MV, Santero S, Breda C, Basilico S, de Filippo G, Luzzi A, Voto L, Cavagnola R, Tomasinelli CE, and Cena H
- Abstract
Objective: Individuals with Autism Spectrum Disorder (ASD) often exhibit a low dietary diversity due to food selectivity that leads them to a marked preference for high-energy-density food, exposing them to risk of malnutrition. Despite these aspects, specific recommendations and targeted menus for this population are missing. The pilot study FOOD-AUT addresses this issue by developing canteen menus meeting the nutritional and sensory needs of adults with ASD, aiming to reduce their food selectivity, and consequently improving their health., Methods: The project, funded by Gruppo Pellegrini S.p.A, was conducted at the daycare service of Sacra Famiglia Onlus Foundation, between March-2022 to March-2023. The study was divided into two phases. Observational phase: a comparison was made between the enrolled subjects' nutritional needs and the nutrient content of the administered menus during the daycare service. Then mealtime compliance was assessed using standardized meal evaluation forms, both quantitative and qualitative. Intervention phase: canteen menus targeted to the individuals' nutritional and sensory needs were administered and their acceptability was evaluated., Results: Twenty-two individuals with ASD, aged 19-48, 72.7% males, were enrolled. Overweight and obesity prevalence were 54.5 and 18.2%, respectively. The observational phase showed how the most accepted foods had specific sensorial characteristics in line with the scientific literature. Adapting the menus improved food acceptance and reduced food waste., Conclusion: The results highlighted the need for adapted menus and greater attention to the way meals are delivered and consumed to improve nutritional status and therefore health of this population at increased risk of malnutrition., Clinical Trial Registration: ClinicalTrial.gov, unique identifier: NCT05978895., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AM declared a shared affiliation with the author AL to the handling editor at the time of review., (Copyright © 2024 Conti, Santero, Breda, Basilico, de Filippo, Luzzi, Voto, Cavagnola, Tomasinelli and Cena.)
- Published
- 2024
- Full Text
- View/download PDF
19. Dietary recommendations to customize canteen menus according to the nutritional and sensory needs of individuals with autism spectrum disorder.
- Author
-
Conti MV, Breda C, Basilico S, Luzzi A, Voto L, Santero S, De Filippo G, and Cena H
- Subjects
- Humans, Diet, Food Preferences, Nutritional Status, Autism Spectrum Disorder, Malnutrition
- Abstract
Individuals with autism spectrum disorders (ASD) are often characterized by food-selectivity, food-neophobia and a marked preference for mild flavor, semi-liquid foods with pale colors. Therefore, they adopt a monotonous dietary pattern, and they prefer ultra-processed food, leading to a high risk of developing malnutrition. In Italy, where 75,072 individuals are diagnosed with ASD, center-based services play a crucial role in their daily management. Despite the centrality of nutrition in maintaining a good state of health, even more for vulnerable subjects, no validated protocol at collective catering level has been developed yet. The manuscript presents customized dietary recommendations aimed at managing the meals for individuals with ASD at collective catering service, derived from a non-systematic literature review exploring food behaviors and nutritional needs in individuals with ASD. Simple practical tips for mealtimes, such as eating together, proper seating, lighting, smell control, presenting food in a simple manner and using the same type of tableware at each meal, to meet the needs of individuals with ASD, were described. The proposal could represent a starting point in developing official guidelines aimed at ASD individuals, in collective catering service.Level of Evidence: Level V., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
20. Economic Impact Analysis of Incorporation of Elecsys sFlt-1/PlGF Ratio Into Routine Practice for the Diagnosis and Follow-Up of Pregnant Women With Suspected Preeclampsia in Argentina.
- Author
-
Garay OU, Guiñazú GG, Basualdo N, Di Marco I, Zilberman J, and Voto L
- Subjects
- Female, Humans, Pregnancy, Argentina, Biomarkers, Follow-Up Studies, Placenta Growth Factor, Pregnant People, Pre-Eclampsia diagnosis, Pre-Eclampsia metabolism
- Abstract
Objectives: Preeclampsia (PE) is a hypertensive disorder of pregnancy that can cause severe complications and adverse fetal/maternal outcomes. We aimed to estimate the annual economic impact of incorporating Elecsys® sFlt-1/PlGF PE ratio, which measures soluble fms-like tyrosine kinase-1 and placental growth factor, into routine clinical practice in Argentina to aid diagnosis of PE and hemolysis, elevated liver enzymes, and low platelets syndrome from second trimester onward in pregnancies with clinical suspicion of PE., Methods: A decision tree was used to estimate annual economic impact on the Argentine health system as a whole, including relevant costs associated with diagnosis, follow-up, and treatment from initial presentation of clinically suspected PE to delivery. Annual costs of a standard-of-care scenario and a scenario including PE ratio (reference year 2021) were analyzed., Results: The economic model estimated that using the sFlt-1/PlGF ratio would enable the overall health system to save ∼$6987 million Argentine pesos annually (95% confidence interval $12 045-$2952 million), a 39.1% reduction in costs versus standard of care, mainly due to reduced hospitalizations of women with suspected PE. The economic impact calculation estimated net annual savings of approximately $80 504 Argentine pesos per patient with suspected PE. Based on the assumed uncertainty of the parameters, the likelihood the intervention would be cost saving was 100% for the considered scenarios., Conclusion: Our analysis suggests that the implementation of the sFlt-1/PlGF ratio in women with suspected PE in Argentina will enable the health system to achieve significant savings, contributing to more efficient clinical management through the likely reduction of unnecessary hospitalizations, depending on assumptions. Results rest on the payers' ability to recover savings generated by the intervention., (Copyright © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
21. Potential Clinical Applications of the Postbiotic Butyrate in Human Skin Diseases.
- Author
-
Coppola S, Avagliano C, Sacchi A, Laneri S, Calignano A, Voto L, Luzzetti A, and Berni Canani R
- Subjects
- Butyrates therapeutic use, Dysbiosis, Humans, Skin microbiology, Microbiota, Skin Diseases drug therapy, Skin Diseases microbiology
- Abstract
Human skin is the largest organ and the most external interface between the environment and the body. Vast communities of viruses, bacteria, archaea, fungi, and mites, collectively named the skin microbiome (SM), cover the skin surface and connected structures. Skin-resident microorganisms contribute to the establishment of cutaneous homeostasis and can modulate host inflammatory responses. Imbalances in the SM structure and function (dysbiosis) are associated with several skin conditions. Therefore, novel target for the skincare field could be represented by strategies, which restore or preserve the SM natural/individual balance. Several of the beneficial effects exerted by the SM are aroused by the microbial metabolite butyrate. Since butyrate exerts a pivotal role in preserving skin health, it could be used as a postbiotic strategy for preventing or treating skin diseases. Herein, we describe and share perspectives of the potential clinical applications of therapeutic strategies using the postbiotic butyrate against human skin diseases.
- Published
- 2022
- Full Text
- View/download PDF
22. Immunonutrition for Pediatric Patients With Cow's Milk Allergy: How Early Interventions Could Impact Long-Term Outcomes.
- Author
-
Carucci L, Coppola S, Luzzetti A, Voto L, Giglio V, Paparo L, Nocerino R, and Berni Canani R
- Abstract
Cow's milk allergy (CMA) is one of the most common food allergies and one of the main causes of food-induced anaphylaxis in the pediatric age. Moreover, up to 45% of CMA children develop other atopic manifestations later in life, a phenomenon commonly named atopic march. Thus, CMA imposes a significant cost to health care systems as well as to families, and has emerged as one of the most expensive allergic diseases. The immunonutrition strategy builds its foundation on the ability of selected dietary factors to modulate immune system development and function. Recent studies highlighted the potential of immunonutrition in the management of CMA. This review is focused on the mechanisms and long-term clinical outcomes of the immunonutrition approach in children with CMA., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Carucci, Coppola, Luzzetti, Voto, Giglio, Paparo, Nocerino and Berni Canani.)
- Published
- 2021
- Full Text
- View/download PDF
23. Tolerability of a new amino acid-based formula for children with IgE-mediated cow's milk allergy.
- Author
-
Nocerino R, Di Scala C, Coppola S, Giglio V, Carucci L, Cosenza L, Voto L, Iannicelli AM, Luzzetti A, and Berni Canani R
- Subjects
- Animals, Cattle, Child, Preschool, Double-Blind Method, Female, Humans, Immunoglobulin E immunology, Infant, Male, Prospective Studies, Skin Tests, Amino Acids therapeutic use, Infant Formula chemistry, Milk Hypersensitivity immunology
- Abstract
Background: Amino acid-based formula (AAF) is a relevant dietary strategy for paediatric patients affected by cow's milk allergy (CMA). The present study was designed to evaluate the hypoallergenicity of a new AAF in children with immunoglobulin (Ig)E-mediated CMA., Methods: According to the criteria provided by the American Academy of Pediatrics Subcommittee on Nutrition and Allergic Diseases, we designed a prospective trial in CMA children (aged 1-36 months) aimed to demonstrate the hypoallergenicity of the new AAF in 90% of subjects with 95% confidence during the double-blind, placebo-controlled challenge (DBPCFC). A skin prick test (SPT) with the new AAF was also performed., Results: Twenty-nine children [all Caucasian, 55.2% male, mean age (±SD) 16.9 ± 5.7 months] were enrolled. The SPT and the DBPCFC with the new AAF were negative in all study subjects., Conclusions: The study results support the hypoallergenicity of the new AAF. This formula could be considered an additional dietary option for non-breastfed children affected by CMA., Trial Registration: The trial was registered in the ClinicalTrials.gov Protocol Registration System (ID number: NCT03909113 ).
- Published
- 2021
- Full Text
- View/download PDF
24. Gut Microbiome as Target for Innovative Strategies Against Food Allergy.
- Author
-
Berni Canani R, Paparo L, Nocerino R, Di Scala C, Della Gatta G, Maddalena Y, Buono A, Bruno C, Voto L, and Ercolini D
- Subjects
- Age Factors, Animals, Diet, Disease Management, Disease Susceptibility, Dysbiosis immunology, Fatty Acids metabolism, Food Hypersensitivity metabolism, Humans, Immune Tolerance, Probiotics, Food Hypersensitivity immunology, Food Hypersensitivity therapy, Gastrointestinal Microbiome drug effects, Gastrointestinal Microbiome immunology
- Abstract
The dramatic increase in food allergy prevalence and severity globally requires effective strategies. Food allergy derives from a defect in immune tolerance mechanisms. Immune tolerance is modulated by gut microbiota function and structure, and microbiome alterations (dysbiosis) have a pivotal role in the development of food allergy. Environmental factors, including a low-fiber/high-fat diet, cesarean delivery, antiseptic agents, lack of breastfeeding, and drugs can induce gut microbiome dysbiosis, and have been associated with food allergy. New experimental tools and technologies have provided information regarding the role of metabolites generated from dietary nutrients and selected probiotic strains that could act on immune tolerance mechanisms. The mechanisms are multiple and still not completely defined. Increasing evidence has provided useful information on optimal bacterial species/strains, dosage, and timing for intervention. The increased knowledge of the crucial role played by nutrients and gut microbiota-derived metabolites is opening the way to a post-biotic approach in the stimulation of immune tolerance through epigenetic regulation. This review focused on the potential role of gut microbiome as the target for innovative strategies against food allergy.
- Published
- 2019
- Full Text
- View/download PDF
25. Ketanserin versus alpha-methyldopa in the treatment of hypertension during pregnancy: a preliminary report.
- Author
-
Voto LS, Zin C, Neira J, Lapidus AM, and Margulies M
- Subjects
- Adult, Blood Pressure drug effects, Clinical Trials as Topic, Female, Fetus drug effects, Humans, Ketanserin adverse effects, Pre-Eclampsia physiopathology, Pregnancy, Random Allocation, Ketanserin therapeutic use, Methyldopa therapeutic use, Pre-Eclampsia drug therapy
- Abstract
The antihypertensive efficacy of acute treatment with the serotonin receptor antagonist, ketanserin, in women with preeclampsia has been recently documented. The purpose of this study was to determine the safety and efficacy of chronic ketanserin treatment in a group of 20 hypertensive pregnant women: 10 received daily oral doses of ketanserin (20-80 mg), and 10 were treated with oral alpha-methyldopa (500-2000 mg). This study includes (a) patients with a sustained elevation of systolic blood pressure higher than 159 mm Hg and/or diastolic blood pressure higher than 99 mm Hg at bed rest, and (b) hypertensive patients with systolic blood pressure higher than 140 mm Hg or diastolic blood pressure higher than 90 mm Hg with superimposed symptoms such as headaches, stomach aches, and neurological disturbances. A significant and comparable decrease in blood pressure was noted in both groups, in relation with pretreatment levels; no adverse affects were observed in mother or fetus from the ketanserin and alpha-methyldopa groups.
- Published
- 1987
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.